Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important for the treatment of heart failure. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.

Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes from the BIONICS and NIREUS Trials. The results support the long-term safety and efficacy of EluNIR Ridaforolimus Eluting Coronary Stent System for the
treatment of patients with coronary artery disease.

Medinol Announces Successful First-in-Human Implantation of ChampioNIR Drug-Eluting Peripheral Stent System in Australia

We are thrilled to announce that our innovative EluNIR-PERL™ DES has received CE approval! This marks a significant milestone in our commitment to advancing cardiovascular care and offering pioneering solutions to patients worldwide.

Dr. Dave noted, “The platinum marker on EluNIR – PERL allows accurate and precise placement in the most challenging coronary anatomy.”

A big thanks to the team at Cardiovascular Experts of PA and CoSo Health for helping patients and saving lives through innovative technology.

CoSo Health partners with Medinol to bring Elunir – PERL to hospitals and ASCs throughout the U.S. and Brazil.

This is a significant milestone in our mission to bring advanced solutions for treating peripheral artery disease.

The EFS will allow us to evaluate the safety and performance of this novel stent technology in a clinical setting. We’re grateful for this opportunity to further our research and development efforts.

Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the treatment of coronary artery disease.

Emotional Case Report that was published in the European Society of Cardiology, European Heart Journal on 18 August 2023: “Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report.”

Prof Eberhard Grube presented the successful FIH implantation of the XEMED TAVR device at the TVT 2023 Structural Heart Summit.

Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel.

We were proud to participate with our EluNIR DES System in the CTO Live Cases from 9 international centers with 26 expert interventional cardiologists on May 31st, 2023.

 Dr. Yoram Richter Medinol’s CEO joined a session on “Innovative stents and valves in cardiac disease” at the UP NEXT summit, Sourasky Medical Center (Ichilov), The first Israeli conference for technological innovation in healthcare.

Our EluNIR DES System was presented last week at the Pavlodar City Cardio Center Conference, Kazakhstan, by our respected local distributor Dan Med LLP.

On PCR 2023, Prof. Maayan Konigstein, Director Interventional Cardiology Catheterization Unit, Tel Aviv Sourasky Medical Center – Ichilov in a lecture on: “The Medinol IoNir hybrid coronary DES system”.

Medinol announces completion of enrollment in its EluNIR HIGH BLEEDING RISK (HBR) trial. A prospective, multi-center, single-arm, open-label post marketing clinical trial, to assess the safety and efficacy of the EluNIR Drug Eluting Stent (DES) in combination with shortened DAPT duration, in patients undergoing PCI who are considered to be at high bleeding risk.